Management of Persistent Facial Tics in Tourette's Syndrome After Medication Discontinuation
For this 12-year-old with persistent facial tics after stopping Lexapro and Strattera, initiate behavioral therapy first (Comprehensive Behavioral Intervention for Tics), and if pharmacologic treatment is needed, start with an alpha-agonist (guanfacine or clonidine) as first-line therapy, followed by atomoxetine as an excellent alternative that can address both tics and any residual ADHD symptoms.
Understanding the Clinical Context
The discontinuation of both escitalopram and atomoxetine was appropriate, as the FDA label data confirms that Strattera (atomoxetine) does not worsen tics in patients with Tourette's disorder 1. The persistence of facial tics after stopping these medications indicates the tics are part of the underlying Tourette's syndrome rather than medication-induced, which is critical for treatment planning.
Tourette syndrome affects approximately 1 per 1,000 male children and commonly presents with neurobehavioral comorbidities including ADHD (50-75%) and obsessive-compulsive behaviors (30-60%) 2. The fact that this patient was on Strattera suggests possible comorbid ADHD, which must be considered in the treatment approach.
Treatment Algorithm
Step 1: Behavioral Therapy as First-Line Treatment
- Comprehensive Behavioral Intervention for Tics (CBIT) should be the initial approach for persistent tic disorders 3
- This is generally considered first-line treatment before pharmacotherapy
- Behavioral therapy can be effective as monotherapy for many patients with troublesome tics
Step 2: Pharmacologic Treatment When Needed
If behavioral therapy is insufficient, inaccessible, or tics cause significant psychological, functional, or physical impairment:
First-Line Pharmacologic Options:
Alpha-agonists (preferred initial choice):
- Guanfacine or clonidine are recommended as first-line pharmacologic agents 4, 5, 6, 7
- These have Level A evidence for treating TS with comorbid ADHD 6
- Particularly beneficial if any hyperactivity symptoms are present 7
- Lower risk profile compared to antipsychotics
- Can address both tics and ADHD symptoms simultaneously
Atomoxetine (excellent alternative):
- Atomoxetine is specifically noted as "an excellent option to treat ADHD and tics" 5
- Clinical trials demonstrated that atomoxetine does not worsen tics in patients with Tourette's disorder 1
- Can be considered as first-line treatment in tic disorders 8
- Particularly appropriate given this patient's history of Strattera use (suggesting possible ADHD comorbidity)
- Non-controlled substance with around-the-clock effects
Second-Line Options (if first-line inadequate):
Atypical antipsychotics:
- Risperidone has the best evidence level among atypical antipsychotics 9
- Aripiprazole has FDA approval for TS and promising data with lower adverse reaction risk 9, 10
- Tiapride (in Europe) has largest clinical experience with low adverse reaction rates 9
Typical antipsychotics (third-line):
- Pimozide has best evidence among typical antipsychotics and showed superiority over haloperidol in efficacy and side effects 2
- Haloperidol is FDA-approved but has more side effects 2
Critical Clinical Considerations
Avoid Iatrogenic Harm
The literature emphasizes that "the major morbidity of habit cough is iatrogenic, resulting from misdiagnosis and excessive treatment" in children 2. This principle applies to tic management—avoid overly aggressive treatment that may cause more harm than the tics themselves.
Assess Functional Impairment
Pharmacologic intervention should only be pursued when tics cause:
- Psychological impairment (embarrassment, social isolation)
- Functional impairment (academic performance, daily activities)
- Physical impairment (pain, injury)
Monitor for Comorbidities
Given the high prevalence of ADHD (50-75%) and OCD (30-60%) in Tourette's syndrome 2, evaluate whether:
- ADHD symptoms persist after Strattera discontinuation
- Obsessive-compulsive symptoms are present
- Anxiety or mood symptoms require attention
Medication Selection Strategy
If ADHD symptoms are prominent:
- Alpha-agonists (clonidine/guanfacine) can address both conditions 6
- Atomoxetine is an excellent choice for combined tic and ADHD management 5, 11
- Stimulants are NOT contraindicated—recent evidence shows they are highly effective in ADHD with comorbid tics and do not worsen tics in the majority of patients 4
If tics are the primary concern:
- Start with alpha-agonists (guanfacine preferred for once-daily dosing and better tolerability)
- Consider risperidone if alpha-agonists fail 9
Common Pitfalls to Avoid
- Don't assume medications caused the tics: The FDA label confirms atomoxetine doesn't worsen tics 1
- Don't rush to antipsychotics: Alpha-agonists and atomoxetine should be tried first due to better safety profiles
- Don't avoid stimulants if ADHD is present: Evidence supports their use even with comorbid tics 4
- Don't treat without assessing impairment: Not all tics require pharmacologic intervention
- Don't forget behavioral therapy: CBIT should be offered before or alongside medication 3
Practical Implementation
Start with:
- Guanfacine: Begin low (0.5-1 mg) and titrate slowly
- OR Clonidine: 0.05 mg and increase gradually (note: may cause more sedation)
- OR Atomoxetine: 0.5 mg/kg/day initially, target 1.2 mg/kg/day 1
Monitor closely for:
- Tic frequency and severity (use standardized scales like YGTSS)
- Sedation, blood pressure changes (with alpha-agonists)
- Mood changes, appetite effects (with atomoxetine)
- Functional improvement in school and social settings
Adjust treatment if:
- No improvement after 4-8 weeks at therapeutic doses
- Intolerable side effects emerge
- Comorbid symptoms become more problematic than tics